WockHardt is a pharmaceutical and biotechnology company headquartered

in Mumbai, India. The company has manufacturing plants in India, UK, Ireland, France and US,
and subsidiaries in US, UK, Ireland and France. It is a global company with more than half of its
revenue coming from Europe. The Company has a market capitalization of over
4,800 crore (US$868.8 million) and an annual turnover of 3,600 crore.
It,produces formulations, biopharmaceuticals, nutrition products, vaccines and active
pharmaceutical ingredients(APIs). WockHardt Hospitals is a subsidiary of the WockHardt
Group.

Wockhardt headquarters, Mumbai
WockHardt was founded by Habil Khorakiwala in the early 1960s. His
father Fakhruddin T. Khorakiwala had acquired Worli Chemical Works in 1959. This was
incorporated as WockHardt Pvt. Ltd., in 1973. WockHardt Ltd. was incorporated on July 8.1999.
WockHardt is often confused as a multinational because of its German sounding name.
WockHardt is the first company outside of the US and Europe to
manufacture recombinant human insulin.
WockHardt acquisitions include Wallis Laboratory, UK (1998), Me rind, India (1998),
CP Pharmaceuticals, UK (2003), Espharma GmbH, Germany (2004), Dumex India (2006),
Pinewood Laboratory, Ireland (2006) and Negma, France (2007). WockHardt debt following the
acquisitions was close to Rs 3,800 crore, and Habil Khorakiwala quit as Managing Director.
The board of directors, on March 31, 2009 approved the appointments of Habil
Khorakiwala's sons Murtaza Khorakiwala and Hozaifa Khorakiwala as Managing Director and
Executive Director respectively..






Wockhardt Ltd.

Type Public (NSE: WOCKPHARMA)
Industry Pharmaceuticals
Health care
Founded 1960s
Founder(s) Habil Khorakiwala
Headquarters Mumbai, India
Area served Worldwide
Key people Habil Khorakiwala (Chairman)
Murtaza Khorakiwala (Managing Director)
Huzaifa Khorakiwala (Executive Director)
Products Formulations
Biopharmaceuticals
Nutrition products
Vaccines
Revenue 3,600 crore (US$651.6 million)